How to Buy morepenlab Shares on Fincept?
You can buy Morepen Laboratories Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Morepen Laboratories Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Morepenlab, including updates on board meetings and corporate actions.
Morepen Laboratories Limited - https://www.morepen.com
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides fever X for fever; Pain X for pain; Fiber-X, a sat isabgol; Acidity X for acidity; Burnol, first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
Morepen Laboratories Limited Share Price Today
63.35
OPEN
64.45
HIGH
62.20
LOW
62.44
CLOSE
2,625 K
VOLUME
4,356 Cr
Market Cap
9390602
Average Volume
Healthcare
Sector
NSI
Exchange
Morepen Laboratories Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: MOREPENLAB Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Morepen Laboratories Limited |
MOREPENLAB |
INE083A01026 |
Annual General Meeting |
20 Sep 2024 |
2 |
N/A |
Morepen Laboratories Limited |
MOREPENLAB |
INE083A01026 |
Annual General Meeting |
21 Sep 2023 |
2 |
N/A |
Morepen Laboratories Limited |
MOREPENLAB |
INE083A01026 |
Annual General Meeting |
19 Sep 2022 |
2 |
N/A |
Morepen Laboratories Limited |
MOREPENLAB |
INE083A01026 |
Annual General Meeting |
20 Sep 2021 |
2 |
N/A |
Morepen Laboratories Limited |
MOREPENLAB |
INE083A01026 |
Annual General Meeting |
22 Sep 2020 |
2 |
N/A |
NSE: MOREPENLAB Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
MOREPENLAB |
30 Dec 2024, 18:07:26 |
Trading Window-XBRL |
Pharmaceuticals |
MOREPENLAB |
30 Dec 2024, 18:02:38 |
Trading Window |
Pharmaceuticals |
MOREPENLAB |
27 Dec 2024, 20:43:57 |
Acquisition-XBRL |
Pharmaceuticals |
MOREPENLAB |
27 Dec 2024, 19:58:16 |
General Updates |
Pharmaceuticals |
MOREPENLAB |
18 Dec 2024, 19:16:02 |
Agreements,Contracts,Arrangements,MOU-XBRL |
Pharmaceuticals |
NSE: MOREPENLAB Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Morepen Laboratories Limited |
MOREPENLAB |
10 Oct 2024, 19:28:00 |
10 Oct 2024, 19:28:00 |
|
Morepen Laboratories Limited |
MOREPENLAB |
18 Jul 2024, 18:58:00 |
18 Jul 2024, 18:58:00 |
|
Morepen Laboratories Limited |
MOREPENLAB |
18 Apr 2024, 13:08:00 |
18 Apr 2024, 13:30:00 |
|
Morepen Laboratories Limited |
MOREPENLAB |
11 Jan 2024, 13:45:00 |
11 Jan 2024, 14:15:00 |
|
Morepen Laboratories Limited |
MOREPENLAB |
12 Oct 2023, 17:47:00 |
12 Oct 2023, 18:15:00 |
NSE: MOREPENLAB Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson & Executive Director-MD |
18 Jan 1964 |
10 Apr 1992 |
00012028 |
SUSHIL SURI |
Active |
Executive Director |
04 Aug 1968 |
13 Aug 2019 |
00041590 |
SANJAY SURI |
Active |
Independent Director |
01 Aug 1968 |
13 Aug 2019 |
06712574 |
PRAVEEN KUMAR DUTT |
Active |
Independent Director |
16 Sep 1959 |
12 Aug 2024 |
00726997 |
RANJIT KHATTAR |
Active |
Independent Director |
01 Jul 1962 |
27 Aug 2024 |
06423452 |
SHARAD JAIN |
Active |
NSE: MOREPENLAB Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
Board Meeting Intimation |
MOREPENLAB |
N/A |
INE083A01026 |
Morepen Laboratories Limited |
06 Nov 2024, 17:00:34 |
MOREPEN LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Aug-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended June 2024 and Dividend. |
MOREPENLAB |
N/A |
INE083A01026 |
Morepen Laboratories Limited |
07 Aug 2024, 17:35:54 |
Financial Results |
MOREPENLAB |
N/A |
INE083A01026 |
Morepen Laboratories Limited |
14 May 2024, 21:09:00 |
MOREPEN LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 22-Feb-2024 to consider and approve Fund raising/Other business. |
MOREPENLAB |
N/A |
INE083A01026 |
Morepen Laboratories Limited |
19 Feb 2024, 17:11:08 |
MOREPEN LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 31-Jan-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended December 2023 . |
MOREPENLAB |
N/A |
INE083A01026 |
Morepen Laboratories Limited |
24 Jan 2024, 15:41:03 |
NSE: MOREPENLAB Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
MOREPENLAB |
- |
INE083A01026 |
Morepen Laboratories Limited |
06 Nov 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 |
Financial Results/Dividend |
MOREPENLAB |
- |
INE083A01026 |
Morepen Laboratories Limited |
07 Aug 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 and dividend for the financial year 2023-24. |
Financial Results |
MOREPENLAB |
- |
INE083A01026 |
Morepen Laboratories Limited |
08 Aug 2024, 00:00:00 |
MOREPENLAB : The Company has informed the Exchange that a Board meeting to be held on August 12, 2024, inter-alia, to consider and approve the financial results for the period ended Jun 30, 2024. The company has recalls the proposal of declaration of final dividend for the financial year 2023-24 and record date. |
Financial Results |
MOREPENLAB |
- |
INE083A01026 |
Morepen Laboratories Limited |
14 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024 |
Fund Raising/Other business matters |
MOREPENLAB |
- |
INE083A01026 |
Morepen Laboratories Limited |
19 Feb 2024, 00:00:00 |
To consider Fund Raising and other business matters |
NSE: MOREPENLAB Balance Sheet Data In (Cr)
| date | period_type | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Non Current Pension And Other Postretirement Benefit Plans | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Investmentin Financial Assets | Available For Sale Securities | Trading Securities | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Restricted Cash | Prepaid Assets | Inventory | Finished Goods | Work In Process | Raw Materials | Other Receivables | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 547,953,699.00 | 547,953,699.00 | 139,492,000.00 | 334,946,000.00 | 10,066,852,000.00 | 11,439,284,000.00 | 6,864,808,000.00 | 10,066,852,000.00 | 11,104,338,000.00 | 11,141,684,000.00 | 11,104,338,000.00 | 0.00 | 11,104,338,000.00 | 10,008,497,000.00 | 0.00 | 0.00 | 1,095,841,000.00 | 1,095,841,000.00 | 4,518,198,000.00 | 453,206,000.00 | 0.00 | 0.00 | 22,495,000.00 | 37,346,000.00 | 37,346,000.00 | 348,309,000.00 | 4,064,992,000.00 | 56,888,000.00 | 297,600,000.00 | 297,600,000.00 | 0.00 | 305,094,000.00 | 2,946,321,000.00 | 0.00 | 0.00 | 0.00 | 2,946,321,000.00 | 15,622,536,000.00 | 4,692,736,000.00 | 874,342,000.00 | 0.00 | 82,294,000.00 | 82,294,000.00 | 0.00 | 1,037,486,000.00 | 292,743,000.00 | 744,743,000.00 | 2,698,255,000.00 | 0.00 | 2,698,255,000.00 | 184,944,000.00 | 2,513,311,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10,929,800,000.00 | 3,059,514,000.00 | 0.00 | 0.00 | 2,823,884,000.00 | 0.00 | 0.00 | 0.00 | 2,243,000.00 | 3,002,007,000.00 | 0.00 | 0.00 | 2,042,152,000.00 | 1,846,698,000.00 | 195,454,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 511,168,708.00 | 511,168,708.00 | 120,541,000.00 | 289,992,000.00 | 7,528,562,000.00 | 8,762,254,000.00 | 4,869,994,000.00 | 7,528,562,000.00 | 8,472,262,000.00 | 8,505,902,000.00 | 8,472,262,000.00 | 0.00 | 8,472,262,000.00 | 7,449,991,000.00 | 2,861,719,000.00 | 4,460,219,000.00 | 1,022,271,000.00 | 1,022,271,000.00 | 4,459,789,000.00 | 439,343,000.00 | 0.00 | 0.00 | 22,495,000.00 | 33,640,000.00 | 33,640,000.00 | 338,166,000.00 | 4,020,446,000.00 | 5,782,000.00 | 256,352,000.00 | 256,352,000.00 | 0.00 | 250,150,000.00 | 3,184,696,000.00 | 197,001,000.00 | 0.00 | 37,420,000.00 | 2,950,275,000.00 | 12,932,051,000.00 | 4,041,611,000.00 | 638,844,000.00 | 71,567,000.00 | 13,010,000.00 | 84,425,000.00 | 13,010,000.00 | 943,700,000.00 | 198,958,000.00 | 744,742,000.00 | 3,012,975,000.00 | -2,614,021,000.00 | 5,626,996,000.00 | 880,934,000.00 | 2,132,041,000.00 | 3,735,658,000.00 | 996,076,000.00 | 14,328,000.00 | 0.00 | 8,890,440,000.00 | -3,000.00 | 351,715,000.00 | 2,568,197,000.00 | 2,485,942,000.00 | 625,497,000.00 | 374,137,000.00 | 1,486,308,000.00 | 65,757,000.00 | 3,249,381,000.00 | -29,362,000.00 | 3,278,743,000.00 | 169,451,000.00 | 495,530,000.00 | 169,451,000.00 | 0.00 | 169,451,000.00 |
| 2024-03-31T00:00:00 | annual | 511,168,708.00 | 511,168,708.00 | 120,541,000.00 | 289,992,000.00 | 7,528,562,000.00 | 8,762,254,000.00 | 4,869,994,000.00 | 7,528,562,000.00 | 8,472,262,000.00 | 8,505,902,000.00 | 8,472,262,000.00 | 0.00 | 8,472,262,000.00 | 7,449,991,000.00 | 2,861,719,000.00 | 4,460,219,000.00 | 1,022,271,000.00 | 1,022,271,000.00 | 4,459,789,000.00 | 439,343,000.00 | 0.00 | 0.00 | 22,495,000.00 | 33,640,000.00 | 33,640,000.00 | 338,166,000.00 | 4,020,446,000.00 | 5,782,000.00 | 256,352,000.00 | 256,352,000.00 | 0.00 | 250,150,000.00 | 3,184,696,000.00 | 197,001,000.00 | 0.00 | 37,420,000.00 | 2,950,275,000.00 | 12,932,051,000.00 | 4,041,611,000.00 | 638,844,000.00 | 71,567,000.00 | 13,010,000.00 | 84,425,000.00 | 13,010,000.00 | 943,700,000.00 | 198,958,000.00 | 744,742,000.00 | 3,012,975,000.00 | -2,614,021,000.00 | 5,626,996,000.00 | 880,934,000.00 | 2,132,041,000.00 | 3,735,658,000.00 | 996,076,000.00 | 14,328,000.00 | 0.00 | 8,890,440,000.00 | -3,000.00 | 351,715,000.00 | 2,568,197,000.00 | 2,485,942,000.00 | 625,497,000.00 | 374,137,000.00 | 1,486,308,000.00 | 65,757,000.00 | 3,249,381,000.00 | -29,362,000.00 | 3,278,743,000.00 | 169,451,000.00 | 495,530,000.00 | 169,451,000.00 | 0.00 | 169,451,000.00 |
| 2023-09-30T00:00:00 | quarterly | 511,168,708.00 | 511,168,708.00 | 44,691,000.00 | 277,554,000.00 | 6,947,808,000.00 | 8,167,502,000.00 | 4,493,204,000.00 | 6,947,808,000.00 | 7,889,948,000.00 | 7,902,623,000.00 | 7,885,338,000.00 | -4,610,000.00 | 7,889,948,000.00 | 6,867,677,000.00 | 0.00 | 0.00 | 1,022,271,000.00 | 1,022,271,000.00 | 4,052,479,000.00 | 390,420,000.00 | 0.00 | 0.00 | 26,860,000.00 | 12,675,000.00 | 12,675,000.00 | 309,009,000.00 | 3,662,059,000.00 | 169,443,000.00 | 264,879,000.00 | 264,879,000.00 | 0.00 | 341,013,000.00 | 2,438,662,000.00 | 0.00 | 0.00 | 0.00 | 2,438,662,000.00 | 11,937,817,000.00 | 3,782,554,000.00 | 644,047,000.00 | 0.00 | 63,777,000.00 | 63,777,000.00 | 0.00 | 942,140,000.00 | 197,398,000.00 | 744,742,000.00 | 2,132,095,000.00 | 0.00 | 2,132,095,000.00 | 199,986,000.00 | 1,932,109,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8,155,263,000.00 | 2,356,003,000.00 | 0.00 | 0.00 | 2,308,261,000.00 | 0.00 | 0.00 | 0.00 | 2,544,000.00 | 2,844,737,000.00 | 0.00 | 0.00 | 643,718,000.00 | 410,855,000.00 | 232,863,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 511,168,708.00 | 511,168,708.00 | 34,983,000.00 | 251,641,000.00 | 6,526,747,000.00 | 7,780,722,000.00 | 4,350,016,000.00 | 6,526,747,000.00 | 7,529,081,000.00 | 7,538,416,000.00 | 7,524,477,000.00 | -4,604,000.00 | 7,529,081,000.00 | 6,506,810,000.00 | 1,900,120,000.00 | 4,460,219,000.00 | 1,022,271,000.00 | 1,022,271,000.00 | 3,580,474,000.00 | 368,843,000.00 | 0.00 | 297,446,000.00 | 26,860,000.00 | 9,335,000.00 | 9,335,000.00 | 297,446,000.00 | 3,211,631,000.00 | 5,782,000.00 | 242,306,000.00 | 242,306,000.00 | 0.00 | 162,411,000.00 | 2,506,707,000.00 | 221,456,000.00 | 0.00 | 16,458,000.00 | 2,268,793,000.00 | 11,104,951,000.00 | 3,543,304,000.00 | 639,177,000.00 | 63,933,000.00 | 0.00 | 63,777,000.00 | 0.00 | 1,002,334,000.00 | 257,592,000.00 | 744,742,000.00 | 2,476,542,000.00 | -3,289,189,000.00 | 5,765,731,000.00 | 806,552,000.00 | 1,669,990,000.00 | 4,036,130,000.00 | 908,721,000.00 | 14,328,000.00 | 0.00 | 7,561,647,000.00 | 2,019,395,000.00 | 346,397,000.00 | 2,048,496,000.00 | 2,288,863,000.00 | 591,289,000.00 | 386,455,000.00 | 1,311,119,000.00 | 28,763,000.00 | 2,632,470,000.00 | -27,541,000.00 | 2,660,011,000.00 | 216,658,000.00 | 401,524,000.00 | 216,658,000.00 | 0.00 | 216,658,000.00 |
| 2023-03-31T00:00:00 | annual | 511,168,708.00 | 511,168,708.00 | 34,983,000.00 | 251,641,000.00 | 6,526,747,000.00 | 7,780,722,000.00 | 4,350,016,000.00 | 6,526,747,000.00 | 7,529,081,000.00 | 7,538,416,000.00 | 7,524,477,000.00 | -4,604,000.00 | 7,529,081,000.00 | 6,506,810,000.00 | 1,900,120,000.00 | 4,460,219,000.00 | 1,022,271,000.00 | 1,022,271,000.00 | 3,580,474,000.00 | 368,843,000.00 | 0.00 | 297,446,000.00 | 26,860,000.00 | 9,335,000.00 | 9,335,000.00 | 297,446,000.00 | 3,211,631,000.00 | 5,782,000.00 | 242,306,000.00 | 242,306,000.00 | 0.00 | 162,411,000.00 | 2,506,707,000.00 | 221,456,000.00 | 0.00 | 16,458,000.00 | 2,268,793,000.00 | 11,104,951,000.00 | 3,543,304,000.00 | 639,177,000.00 | 63,933,000.00 | 0.00 | 63,777,000.00 | 0.00 | 1,002,334,000.00 | 257,592,000.00 | 744,742,000.00 | 2,476,542,000.00 | -3,289,189,000.00 | 5,765,731,000.00 | 806,552,000.00 | 1,669,990,000.00 | 4,036,130,000.00 | 908,721,000.00 | 14,328,000.00 | 0.00 | 7,561,647,000.00 | 2,019,395,000.00 | 346,397,000.00 | 2,048,496,000.00 | 2,288,863,000.00 | 591,289,000.00 | 386,455,000.00 | 1,311,119,000.00 | 28,763,000.00 | 2,632,470,000.00 | -27,541,000.00 | 2,660,011,000.00 | 216,658,000.00 | 401,524,000.00 | 216,658,000.00 | 0.00 | 216,658,000.00 |
| 2022-03-31T00:00:00 | annual | 477,826,203.00 | 477,826,203.00 | 27,664,000.00 | 185,690,000.00 | 4,731,532,000.00 | 5,971,302,000.00 | 2,778,442,000.00 | 4,731,532,000.00 | 5,785,612,000.00 | 5,798,823,000.00 | 5,781,005,000.00 | -4,607,000.00 | 5,785,612,000.00 | 262,500,000.00 | 1,513,368,000.00 | 3,080,384,000.00 | 955,586,000.00 | 955,586,000.00 | 4,919,522,000.00 | 354,953,000.00 | 0.00 | 282,445,000.00 | 24,826,000.00 | 13,211,000.00 | 13,211,000.00 | 282,445,000.00 | 4,564,569,000.00 | 5,786,000.00 | 172,479,000.00 | 172,479,000.00 | 0.00 | 122,369,000.00 | 2,631,801,000.00 | 0.00 | 0.00 | 50,645,000.00 | 2,581,156,000.00 | 10,700,527,000.00 | 3,357,516,000.00 | 1,000.00 | 58,669,000.00 | 0.00 | 0.00 | 0.00 | 1,054,080,000.00 | 309,338,000.00 | 744,742,000.00 | 2,244,194,000.00 | -3,166,240,000.00 | 5,410,434,000.00 | 777,723,000.00 | 1,466,472,000.00 | 3,804,307,000.00 | 814,076,000.00 | 14,328,000.00 | 0.00 | 7,343,011,000.00 | -1,000.00 | 301,680,000.00 | 1,583,342,000.00 | 2,758,541,000.00 | 795,205,000.00 | 358,217,000.00 | 1,605,119,000.00 | 34,992,000.00 | 2,506,431,000.00 | -58,287,000.00 | 2,564,718,000.00 | 158,026,000.00 | 352,309,000.00 | 158,026,000.00 | 11,302,000.00 | 146,724,000.00 |
| 2021-03-31T00:00:00 | annual | 449,826,203.00 | 449,826,203.00 | 0.00 | 170,457,000.00 | 3,292,568,000.00 | 4,417,955,000.00 | 1,229,910,000.00 | 3,292,568,000.00 | 4,247,498,000.00 | 4,255,781,000.00 | 4,242,905,000.00 | -4,593,000.00 | 4,247,498,000.00 | 437,500,000.00 | 546,542,000.00 | 2,386,384,000.00 | 899,586,000.00 | 899,586,000.00 | 4,338,555,000.00 | 300,555,000.00 | 0.00 | 253,930,000.00 | 0.00 | 8,283,000.00 | 8,283,000.00 | 253,930,000.00 | 4,038,000,000.00 | 5,806,000.00 | 162,174,000.00 | 162,174,000.00 | 0.00 | 52,510,000.00 | 2,215,011,000.00 | 0.00 | 97,916,000.00 | 28,606,000.00 | 2,088,489,000.00 | 8,581,460,000.00 | 3,313,550,000.00 | 1,037,284,000.00 | 48,556,000.00 | 10,850,000.00 | 10,850,000.00 | 10,850,000.00 | 954,930,000.00 | 210,188,000.00 | 744,742,000.00 | 2,298,609,000.00 | -3,709,802,000.00 | 6,008,411,000.00 | 1,005,757,000.00 | 1,292,852,000.00 | 4,194,273,000.00 | 792,559,000.00 | 15,822,000.00 | 0.00 | 5,267,910,000.00 | 1,007,305,000.00 | 265,073,000.00 | 924,827,000.00 | 1,753,257,000.00 | 624,319,000.00 | 436,580,000.00 | 692,358,000.00 | 91,042,000.00 | 1,819,842,000.00 | -51,610,000.00 | 1,871,452,000.00 | 413,869,000.00 | 270,893,000.00 | 413,869,000.00 | 0.00 | 413,869,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1,941,025,000.00 | 238,235,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27,197,000.00 | 0.00 | 0.00 | 0.00 | 93,024,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: MOREPENLAB Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Beginning Cash Position | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Net Common Stock Issuance | Common Stock Issuance | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Net Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Net Investment Purchase And Sale | Net Intangibles Purchase And Sale | Purchase Of Intangibles | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Pension And Employee Benefit Expense | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | -79,609,000.00 | 0.00 | -813,355,000.00 | 169,451,000.00 | 216,658,000.00 | -47,207,000.00 | 52,049,000.00 | 50,800,000.00 | -37,102,000.00 | 0.00 | 0.00 | 38,351,000.00 | 14,046,000.00 | 24,305,000.00 | -833,002,000.00 | -7,169,000.00 | -13,010,000.00 | -99,547,000.00 | -99,547,000.00 | -713,276,000.00 | 532,000.00 | -713,808,000.00 | 733,746,000.00 | -381,153,000.00 | -581,232,000.00 | 794,768,000.00 | 0.00 | -197,079,000.00 | -1,178,921,000.00 | 37,102,000.00 | 334,695,000.00 | 157,810,000.00 | 176,885,000.00 | -27,524,000.00 | 2,305,000.00 | 0.00 | 1,354,157,000.00 |
| 2023-03-31T00:00:00 | annual | -1,371,426,000.00 | 1,371,520,000.00 | -459,720,000.00 | 216,658,000.00 | 158,026,000.00 | 58,632,000.00 | 1,435,431,000.00 | 17,768,000.00 | -19,808,000.00 | 1,371,520,000.00 | 1,371,520,000.00 | 65,951,000.00 | 69,827,000.00 | -3,876,000.00 | -465,093,000.00 | -5,373,000.00 | 0.00 | -103,514,000.00 | -103,514,000.00 | -356,206,000.00 | 0.00 | -356,206,000.00 | -911,706,000.00 | -165,539,000.00 | -1,582,767,000.00 | -1,422,764,000.00 | 0.00 | 469,678,000.00 | -629,681,000.00 | 19,808,000.00 | 279,304,000.00 | 155,296,000.00 | 124,008,000.00 | -20,062,000.00 | 0.00 | 0.00 | 557,553,000.00 |
| 2022-03-31T00:00:00 | annual | -1,276,082,000.00 | 525,000,000.00 | -673,680,000.00 | 158,026,000.00 | 413,869,000.00 | -255,843,000.00 | 663,344,000.00 | 123,111,000.00 | 0.00 | 525,000,000.00 | 525,000,000.00 | 15,233,000.00 | 10,305,000.00 | 4,928,000.00 | -316,785,000.00 | 339,813,000.00 | 15,411,000.00 | -219,218,000.00 | -219,218,000.00 | -452,791,000.00 | 1,671,000.00 | -454,462,000.00 | -602,402,000.00 | -249,323,000.00 | -1,814,687,000.00 | 516,260,000.00 | 24,826,000.00 | -1,005,287,000.00 | -1,325,660,000.00 | -73,655,000.00 | 276,425,000.00 | 0.00 | 276,425,000.00 | -4,600,000.00 | 0.00 | -3,602,000.00 | 1,267,026,000.00 |
| 2021-03-31T00:00:00 | annual | 104,273,000.00 | 437,500,000.00 | -403,984,000.00 | 413,869,000.00 | 136,391,000.00 | 277,478,000.00 | 472,728,000.00 | 17,334,000.00 | -17,882,000.00 | 437,500,000.00 | 437,500,000.00 | 35,776,000.00 | 39,649,000.00 | -3,873,000.00 | -703,507,000.00 | -299,573,000.00 | 0.00 | -185,989,000.00 | -185,989,000.00 | -217,945,000.00 | 50,000.00 | -217,995,000.00 | 508,257,000.00 | -14,637,000.00 | -781,842,000.00 | 486,825,000.00 | 0.00 | -368,500,000.00 | -900,167,000.00 | 17,882,000.00 | 302,833,000.00 | 0.00 | 302,833,000.00 | -1,050,000.00 | 0.00 | -3,000.00 | 985,115,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -19,845,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: MOREPENLAB Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Research And Development | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 0.00 | 0.00 | 172.60 | 96.16 | 33.47 | 1,083.52 | 172.60 | 139.13 | -1.21 | 3.71 | 2.50 | 96.16 | 96.16 | 1,556.98 | 12.08 | 51.12 | 51.12 | 0.00 | 0.00 | 96.16 | 96.16 | 0.00 | 96.16 | -0.46 | 96.62 | 96.62 | 38.80 | 135.42 | 11.47 | -1.21 | 0.00 | 3.71 | 2.50 | 125.16 | 473.46 | 122.23 | 33.47 | 0.00 | 33.47 | 5.20 | 127.31 | 109.98 | 17.34 | 12.08 | 598.61 | 1,083.52 | 1,682.13 | 1,682.13 |
| 2023-03-31T00:00:00 | annual | 0.00 | 0.00 | 85.67 | 38.68 | 27.93 | 970.37 | 85.67 | 57.74 | -0.32 | 1.98 | 1.66 | 38.68 | 38.68 | 1,362.35 | 10.74 | 50.22 | 50.22 | 0.00 | 0.00 | 38.68 | 38.68 | 0.00 | 38.68 | 0.00 | 38.68 | 38.68 | 17.08 | 55.76 | 4.48 | -0.32 | 0.00 | 1.98 | 1.66 | 51.60 | 391.98 | 91.96 | 27.93 | 0.00 | 27.93 | 3.07 | 107.18 | 93.01 | 14.16 | 10.74 | 443.58 | 970.37 | 1,413.95 | 1,413.95 |
| 2022-03-31T00:00:00 | annual | 0.00 | 0.00 | 156.77 | 101.68 | 27.64 | 1,060.94 | 156.77 | 129.13 | -1.10 | 2.43 | 1.33 | 101.68 | 101.68 | 1,432.54 | 8.18 | 51.98 | 45.00 | 0.00 | 0.00 | 101.68 | 101.68 | 0.00 | 101.68 | 0.00 | 101.68 | 101.68 | 25.02 | 126.70 | 8.98 | -1.10 | 0.00 | 2.43 | 1.33 | 109.03 | 371.60 | 106.02 | 27.64 | 0.00 | 27.64 | 3.01 | 67.76 | 53.58 | 14.19 | 8.18 | 480.63 | 1,060.94 | 1,541.57 | 1,541.57 |
| 2021-03-31T00:00:00 | annual | 0.00 | 0.00 | 130.09 | 97.09 | 30.28 | 786.78 | 130.09 | 99.81 | 0.35 | 1.30 | 2.13 | 97.09 | 97.09 | 1,087.14 | 5.14 | 45.11 | 44.98 | 0.00 | 0.00 | 97.09 | 97.09 | 0.00 | 97.09 | 0.00 | 97.09 | 97.09 | 1.42 | 98.51 | 9.93 | 0.35 | 0.49 | 1.30 | 2.13 | 88.23 | 300.36 | 74.56 | 30.28 | 0.00 | 30.28 | 5.65 | 61.83 | 49.66 | 12.17 | 5.14 | 388.59 | 786.78 | 1,175.37 | 1,175.37 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
5/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
2.53
P/E
31.411068
P/B
3.8369062
Dividend Yield
N/A
Market Cap
4,356.22 Cr.
Face Value
20.712
Book Value
20.712
ROE
7.4%
EBITDA Growth
193.26 Cr.
Debt/Equity
3.016
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of morepenlab?
The market capitalization of Morepen Laboratories Limited is ₹4,356 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Morepen Laboratories Limited?
The PE and PB ratios of Morepen Laboratories Limited are Not Available and 3.8369062 respectively as of 05 Feb 2025.
What is the 52 Week High of Morepen Laboratories Limited?
The 52-week high of Morepen Laboratories Limited is ₹100.9 as of 05 Feb 2025.
What is the 52 Week Low of Morepen Laboratories Limited?
The 52-week low of Morepen Laboratories Limited is ₹38.55 as of 05 Feb 2025.
What are the earnings per share (EPS) for Morepen Laboratories Limited?
The Earnings Per Share (EPS) of Morepen Laboratories Limited is ₹2.53 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Morepen Laboratories Limited?
The Return on Equity (ROE) of Morepen Laboratories Limited is 7.4% as per the most recent financial year data. Explore more on Fincept.